General Manager R&D and Operations, AstraZeneca

Mark Proctor was recently appointed as the General Manager of AstraZeneca’s R&D and Operations site in Liverpool, UK, which is primarily responsible for the development, manufacture, and release of the sterile bulk drug substance for the seasonal Live Attenuated Influenza Vaccine.  Mark previously worked at this site (2009 to 2015) as the MS&T / CMC Director where he played a key role in the introduction of the quadrivalent vaccine formulation, setup the R&D team in Liverpool, and delivered a multi-award winning manufacturing automation program.

 In 2015, Mark left the site to lead AstraZeneca’s Global Technical Services team responsible for providing CMC support for all marketed products across the world. In 2017, he moved into a strategic brand leadership role as a Global Supply & Strategy Snr. Director responsible for new product launch and supply chain strategy. Most recently Mark led the Global Supply Teams responsible for the Oxford/AstraZeneca Covid vaccine for SARS-CoV-2 in the UK and Internationally.

 Before joining AstraZeneca Mark worked for BioPharm Services, a specialist biopharmaceutical consultancy. He is a Fellow of the Institute of Chemical Engineers, holds a Master’s degree in Biochemical Engineering (UCL), and an Executive MBA (Cass Business School). He was awarded the rank of CBE in the 2021 Queen’s Birthday Honours in recognition of his services to the Covid-19 response.


23 September 2021